We excluded patients with IDH1-mutant gliomas (Supplementary Table 2) because IDH1 mutations are associated with favorable survival and are not included in the GBM classification in the 2021 World Health Organization Classification of Tumors of the Central Nervous System [2]. This evidence concerns the gene IDH1 and glioblastoma.